JC-Virus (JCV) Antibody Program

Completed

Conditions studied: Multiple Sclerosis

In brief

The primary objective is to define the prevalence of serum anti-JCV antibody in relapsing multiple sclerosis (MS) participants receiving Tysabri® (natalizumab) or being considered for such treatment. Secondary objectives are to analytically validate the anti-JCV antibody assay in a plasma matrix and to determine changes in anti-JCV antibody status over time.

Key facts

Study ID

NCT01070823

Run by

Biogen

People needed

1096

Starts

2010-03-01

Expected to finish

2012-06-01

Last updated by the study team

2016-10-05

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Aurora, Colorado, United States
• Research Site — Atlanta, Georgia, United States
• Research Site — Cullman, Georgia, United States
• Research Site — Barrington, Illinois, United States
• Research Site — Brighton, Massachusetts, United States
• Research Site — Farmington Hills, Michigan, United States
• Research Site — Raleigh, North Carolina, United States
• Research Site — Portland, Oregon, United States
• Research Site — Round Rock, Texas, United States
• Research Site — Salt Lake City, Utah, United States
• Research Site — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.